Topiramate (TPM) is a novel neurotherapeutic agent currently indicated for
the treatment of epilepsy and undergoing development for other central nerv
ous system indications including neuropathic pain, bipolar disorder, and mi
graine prophylaxis. TPM is synthesized from D-fructose and contains a sulfa
mate moiety that is essential for its pharmacologic activity. TPM has been
observed to significantly reduce bodyweight in patients treated for seizure
, which has prompted the realization of preclinical studies to characterize
the effects of TPM in the regulation of energy balance. Studies carried ou
t in various strains of rats have provided good evidence for the ability of
TPM to blunt-energy deposition. Body composition analyses from rat trials
have demonstrated that TPM inhibits fat deposition while reducing the activ
ity of lipoprotein lipase (LPL)in various white adipose tissue depots. High
doses of TPM (likely above the therapeutic dose range) have also been obse
rved to reduce protein gain without catabolic effects. Although TPM cannot
be described as a potent anorectic agent, it seems to have the ability to r
educe food intake; significant reductions in food intake have been observed
in female obese (fa/fa) Zucker rats and in female Wistar rats. TPM can als
o reduce energy deposition in the absence of alterations in food intake. Th
is effect has been clearly emphasized in female lean (Fa/?) Zucker rats. In
female Sprague-Dawley rats, TPM also increased energy expenditure and it h
as been observed to increase LPL activity: in brown adipose tissue, which c
ould indicate that TPM has the ability to enhance regulatory thermogenesis.
In addition, TPM stimulates LPL activity in skeletal muscles, further emph
asizing its potential to promote substrate oxidation. The mechanisms whereb
y TPM affects the regulation of energy-balance have yet to be understood. T
PM represents an antiepileptic drug (AED) with complex biochemical/pharmaco
logic actions. Its negative effects on energy deposition cannot be readily
predicted from these actions, as AEDs are generally expected to stimulate b
ody weight gain. Recent data, obtained from investigations aimed at assessi
ng the effects of TPM on neuropeptidergic systems involved in the regulatio
n of energy balance, have failed to demonstrate any significant effects of
TPM on the neuropeptide Y and proopiomelanocortin systems. In conclusion it
is clear that TPM can reduce fat deposition by either reducing food intake
or stimulating energy expenditure. The mechanisms whereby an AED such as T
PM controls food intake and energy expenditure remains to be delineated. Nu
trition 2000;16:961-966. (C) Elsevier Science Inc. 2000.